First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

BACKGROUND: -positive NSCLC is unclear. METHODS: -positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objecti... View More